We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Serum Antinuclear Antibody Correlated in Hispanic Pediatric Patients With NFLD

By LabMedica International staff writers
Posted on 06 Apr 2022

Non-alcoholic fatty liver disease (NAFLD), also known as metabolic (dysfunction) associated fatty liver disease (MAFLD), is excessive fat build-up in the liver without another clear cause such as alcohol use. More...

Obesity and type 2 diabetes are strong risk factors for NAFLD.

Blood tests that are useful to confirm diagnosis or rule out others include erythrocyte sedimentation rate, glucose, albumin, and kidney function. Because the liver is important for making proteins used in blood clotting, coagulation-related studies are often carried out, especially the international normalized ratio (INR).

Clinical Scientists at the Yale New Haven Hospital (New Haven, CT, USA) and their colleagues examined the significance of antinuclear antibody (ANA) positivity in pediatric Hispanic patients with nonalcoholic fatty liver disease. ANA status was correlated with clinical, laboratory, and histologic parameters in Hispanic patients with a histologic diagnosis of NAFLD. In their study, they included 38 Hispanic children (27 male and 11 female) who had underwent a liver biopsy at a median age of 12.1 years.

The investigators reported that 20 patients (53%) had positive ANAs. The ANA-positive patients had higher fasting insulin levels (median = 32.4 µU/mL) and higher insulin resistance ([Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) median = 5.9) than the ANA-negative patients (fasting insulin: median = 17 µU/mL and median [HOMA-IR 3.5 µU/mL). Serum high-density lipoprotein (HDL) cholesterol levels were higher in the ANA-negative patients (median = 47 mg/dL) than the ANA-positive patients (38 mg/dL). There were no statistical differences in a series of demographic, clinical, laboratory, and histologic parameters between the ANA-positive and the ANA-negative patients. At a median follow-up of 2.6 years, alanine aminotransferase was significantly lower than the baseline levels in both groups.

The authors concluded that in pediatric Hispanic patients with NAFLD, a positive ANA result is associated with insulin resistance and lower HDL cholesterol levels. The study was published on March 21, 2022 in the American Journal of Clinical Pathology.

Related Links:
Yale New Haven Hospital


New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Portable Electronic Pipette
Mini 96
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.